Which roads lead to access? A global landscape of six COVID-19 vaccine innovation models.

ABSTRACT:

Background

Unequal and inequitable access to Covid-19 vaccines in low- and middle-income countries (L&MICs) was a major political, ethical and public health failure in the pandemic. However, vaccine developers' practices were not monolithic, but rather, took diverse approaches to supplying different countries, with important implications for global access.

Results

Using data on R&D investments, regulatory approvals, manufacturing and purchase agreements, and vaccine deliveries, we identified six distinct innovation models that apply across the 14 COVID-19 vaccines with more international presence from 2020-2022. "Western Early Arrivers" Pfizer/BioNTech and Moderna supplied the largest volumes quickly and prioritized high-income countries (HICs) from registration to vaccine d

SUBMITTER: Alonso Ruiz A 

PROVIDER: S-EPMC10964709 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature